1. Chimeric Drug Design with a Noncharged Carrier for Mitochondrial Delivery
- Author
-
Pilar Herrero-Foncubierta, M. Carmen Gonzalez-Garcia, Emilio Garcia-Fernandez, Johan Hofkens, Maria J. Ruedas-Rama, Delia Miguel, Herlinde De Keersmaecker, Jose M. Paredes, Consuelo Ripoll, Mar Roldan, Susana Rocha, Juan M. Cuerva, Angel Orte, Sandra Resa, Miguel Martín, Virginia Puente-Muñoz, [Ripoll,C, Herrero-Foncubierta,P, Puente-Muñoz,V, Gonzalez-Garcia,MC, Delia,M, Paredes,JM, Ruedas-Rama,MJ, Garcia-Fernandez,E, Orte,A] Departamento de Fisicoquimica, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente, Facultad de Farmacia, Universidad de Granada, Granada, Spain. [Herrero-Foncubierta,P, Resa,S, Cuerva,JM] Departamento de Quimica Organica, Unidad de Excelencia de Química Aplicada a Biomedicina y Medioambiente, Facultad de Ciencias, Universidad de Granada, Granada, Spain. [Roldan,M, Martin,M] GENYO, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Granada, Spain. [Rocha,S, De Keersmaecker,H, Hofkens,J] Department of Chemistry, K. U. Leuven, Celestijnenlaan, Heverlee, Belgium., This research: including APC charges, was funded by the Spanish Agencia Estatal de Investigación (Ministry of Science and Innovation) and the European Regional Development Fund [grant numbers CTQ2014-56370-R, CTQ2014-53598, and CTQ2017-85658-R], Fundación Ramón Areces, and and the initiative Solidaridad Entre Montañas. J.H. acknowledges financial support from the Flemish government through long-term structural funding Methusalem (CASAS2, Meth/15/04).
- Subjects
Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Pharmacology::Chemistry, Pharmaceutical [Medical Subject Headings] ,Drug ,analytical_chemistry ,mitochondrial carrier ,Fluorescence-lifetime imaging microscopy ,Chemicals and Drugs::Organic Chemicals::Sulfur Compounds::Thiophenes [Medical Subject Headings] ,Pyruvate dehydrogenase kinase ,Activación metabólica ,media_common.quotation_subject ,lcsh:RS1-441 ,Pharmaceutical Science ,Mitochondrion ,01 natural sciences ,Article ,antitumor agents ,lcsh:Pharmacy and materia medica ,03 medical and health sciences ,chemistry.chemical_compound ,medicinal chemistry ,Thiophene ,Phenomena and Processes::Metabolic Phenomena::Metabolism [Medical Subject Headings] ,Moiety ,Pharmacology & Pharmacy ,Mitocondrias ,Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria [Medical Subject Headings] ,030304 developmental biology ,media_common ,0303 health sciences ,Science & Technology ,010405 organic chemistry ,metabolic drug ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings] ,Transporter ,Antineoplásicos ,Mitochondrial carrier ,CANCER ,fluorescence lifetime imaging ,0104 chemical sciences ,Química farmacéutica ,Biochemistry ,chemistry ,Biophysics ,Tiofenos ,Life Sciences & Biomedicine - Abstract
Recently, it was proposed that the thiophene ring is capable of promoting mitochondrial accumulation when linked to fluorescent markers. As a noncharged group, thiophene presents several advantages from a synthetic point of view, making it easier to incorporate such a side moiety into different molecules. Herein, we confirm the general applicability of the thiophene group as a mitochondrial carrier for drugs and fluorescent markers based on a new concept of nonprotonable, noncharged transporter. We implemented this concept in a medicinal chemistry application by developing an antitumor, metabolic chimeric drug based on the pyruvate dehydrogenase kinase (PDHK) inhibitor dichloroacetate (DCA). The promising features of the thiophene moiety as a noncharged carrier for targeting mitochondria may represent a starting point for the design of new metabolism-targeting drugs. ispartof: PHARMACEUTICS vol:13 issue:2 ispartof: location:Switzerland status: published
- Published
- 2021
- Full Text
- View/download PDF